Abstract: The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.

Abstract: The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.

Abstract: The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.

Abstract: Methods of treating cancer, tumor angiogenesis, viral infection and fungal entry are provided. These methods include administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes a compound that inhibits pro-to-oncogene tyrosine kinase protein SRC (c-SRC). The inhibition of SRC blocks cell surface glucose-regulated protein GRP78 and/or other endoplasmic reticulum ER luminal proteins dependent on SRC from going to the cell surface.

Abstract: This invention relates to compositions and methods for modulating apoptosis by regulating the activity of endoplasmic reticulum transmembrane glucose regulated protein 78 (GRP78).

Abstract: This invention relates to compositions and methods for modulating apoptosis by regulating the activity of endoplasmic reticulum transmembrane glucose regulated protein 78 (GRP78).

Abstract: This invention relates to compositions and methods for selective expression of a heterologous nucleic acid sequence in a targeted tissue, and more particularly to the glucose regulated protein 78 (grp78) stress-responsive promoter and its use in gene therapy and the production of transgenic animals.

Abstract: Methods of preventing or reducing tumor angiogenesis in a subject, comprising administering to the subject one or more agents that inhibit expression or activity of GRP78 are provided. Also provided are methods of sensitizing tumor blood vessels to a chemotherapeutic agent comprising administering to the subject one or more agents that inhibit expression or activity of GRP78. Provided is also a method of reducing tumor microvessel density in a subject, comprising selecting a subject with a tumor, wherein the subject is in need of reduction of tumor microvessel density, and administering to the subject one or more agents that inhibit expression or activity of GRP78.

Abstract: The present application provides methods for detecting, diagnosing, monitoring, predicting responsiveness to therapeutic agents and staging cancer. The present application provides methods and compositions useful for suppression of GRP78 expression or activity in cancer cells to overcome resistance of certain therapeutic agents. The present application also provides methods for predicting whether a subject with cancer is at risk for developing resistance to certain therapeutic agents.

Abstract: This invention relates to compositions and methods for selective expression of a heterologous nucleic acid sequence in a targeted tissue, and more particularly to the glucose regulated protein 78 (grp78) stress-responsive promoter and its use in gene therapy and the production of transgenic animals.

Abstract: The regulatory sequence for a glucose regulated protein has been isolated. When fused into suitable expression vectors within reading relationship of a desired polypeptide DNA sequence, the resulting hybrid gene can be induced to high levels by glucose starvation, or calcium shock, or by denaturing reagents such as .beta.-mercaptoethanol, in a variety of host systems. Further, the hybrid gene can also be regulated by temperature when it is introduced into temperature-sensitive host systems such as the temperature-sensitive mutant of Chinese hamster cells or other systems having a compatible mutation.